Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
AstraZeneca
QuintilesIMS
Harvard Business School
US Army
Baxter

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,307,419

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,307,419 protect, and when does it expire?

Patent 10,307,419 protects REXULTI and is included in one NDA.

This patent has twenty-six patent family members in twenty countries.

Summary for Patent: 10,307,419
Title:Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl -piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4 -yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer, containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
Inventor(s): Inoue; Yoshiharu (Osaka, JP)
Assignee: OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:15/713,427
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,307,419

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-001 Jul 10, 2015 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-002 Jul 10, 2015 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-003 Jul 10, 2015 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-004 Jul 10, 2015 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,307,419

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2011-227057Oct 14, 2011

International Family Members for US Patent 10,307,419

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 088319   Try a Free Trial
Australia 2012321723   Try a Free Trial
Brazil 112014008603   Try a Free Trial
Canada 2851588   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Deloitte
Healthtrust
Mallinckrodt
Queensland Health
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.